Development of Modified-Release Tablets of Zolpidem Tartrate by Biphasic Quick/Slow Delivery System
Journal Title: AAPS PharmSciTech - Year 2015, Vol 16, Issue 3
Abstract
Zolpidem tartrate is a non-benzodiazepine analogue of imidazopyridine of sedative and hypnotic category. It has a short half-life with usual dosage regimen being 5 mg, two times a day, or 10 mg, once daily. The duration of action is considered too short in certain circumstances. Thus, it is desirable to lengthen the duration of action. The formulation design was implemented by preparing extended-release tablets of zolpidem tartrate using the biphasic delivery system technology, where sodium starch glycolate acts as a superdisintegrant in immediate-release part and hydroxypropyl methyl cellulose as a release retarding agent in extended-release core. Tablets were prepared by direct compression. Both the core and the coat contained the drug. The pre-compression blends were evaluated for angle of repose, bulk density, and compressibility index. The tablets were evaluated for thickness, hardness, weight variation test, friability, and in vitro release studies. No interaction was observed between zolpidem tartrate and excipients from the Fourier transform infrared spectroscopy and differential scanning calorimetry analysis. The results of all the formulations prepared were compared with reference product Stilnoct®. Optimized formulations showed release patterns that match the United States Pharmacopeia (USP) guidelines for zolpidem tartrate extended-release tablets. The mechanism of drug release was studied using different mathematical models, and the optimized formulation has shown Fickian diffusion. Accelerated stability studies were performed on the optimized formulation.
Authors and Affiliations
Anjan Kumar Mahapatra, N. H. Sameeraja, P. N. Murthy
Keywords
Related Articles
- EP ID EP682238
- DOI 10.1208/s12249-014-0236-2
- Views 103
- Downloads 0
Surface Acidity and Solid-State Compatibility of Excipients with an Acid-Sensitive API: Case Study of Atorvastatin Calcium
The online version of this article (doi:10.1208/s12249-014-0231-7) contains supplementary material, which is available to authorized users.
Recent Trends in Product Development and Regulatory Issues on Impurities in Active Pharmaceutical Ingredient (API) and Drug Products. Part 2: Safety Considerations of Impurities in Pharmaceutical Products and Surveying the Impurity Landscape
There are inconsistent identification and qualification thresholds for impurities in drug substances and drug products, particularly for degradation impurities that may be common to both a drug substance and a correspond...
Electrospinning of Cross-Linked Magnetic Chitosan Nanofibers for Protein Release
Iron(III) chloride hexahydrate (FeCl3.6H2O), (FeCl2·4H2O) was purchased from Merck Co. Medium molecular weight chitosan (CTS, 75 and 85% deacetylated), bovine serum albumin (BSA), and acetic acid (TFA, _98%) were...
Defining the Critical Material Attributes of Lactose Monohydrate in Carrier Based Dry Powder Inhaler Formulations Using Artificial Neural Networks
The study aimed to establish a function-based relationship between the physical and bulk properties of pre-blended mixtures of fine and coarse lactose grades with the in vitro performance of an adhesive active pharmaceut...
Development and Evaluation of New Microemulsion-Based Hydrogel Formulations for Topical Delivery of Fluconazole
The aim of the present investigation was to develop and evaluate microemulsion-loaded hydrogels (MEHs) for the topical delivery of fluconazole (FZ). The solubility of FZ in oils, surfactants and cosurfactants was evaluat...